VIDEO: Immunotherapy may offer next big breakthrough in advanced prostate cancer

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We've been unfortunately left out of the immunotherapy space. Obviously, we have Sipuleucel-T, but that has a modest benefit. All of the studies that have been done with checkpoint inhibitors, for the most part as single agent treatment, have not really shown significant benefit, except for the very small percentage of patients with prostate cancer who have MSI-high tumors or TMB-high tumors. It's still a very small percentage. So I think that we're gonna see, in particular, bispecific antibodies or BiTE therapies, so-called T-cell engagers, bispecific T-cell engagers, that are gonna basically bring immune treatments to killing cancer cells.

And I think that's gonna be an important area. The other important area I think that we're gonna continue to see developments in is improvements in radioligand therapy and also antibody drug conjugates. So obviously these are all hot topics within the broader field of cancer therapy, but I think that they will be used in prostate cancer in particular because we have good targets in prostate cancer. We have PSMA, there are others like DLL3 for neuroendocrine prostate cancer.

And I think that the ability to deliver either a toxic payload of radioactive material or a targeted chemotherapy or immunotherapy, whatever we actually attach to that targeted treatment, I think will show better and better efficacy. So I think it's not a single approach. I think they all share a common mechanism, but I think those will be the biggest breakthroughs in the next few years.